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Pemphigus foliaceus is an autoimmune disease that is sporadic around the world
but endemic in Brazil, where it is known as fogo selvagem (FS). Characterized by
autoantibodies against the desmosomal cadherin desmoglein 1, FS causes painful
erosions, and crusts that may be widespread. The recognition of antigens, including
exposed sugar moieties, activates the complement system. Complement receptor 1
(CR1, CD35), which is responsible for the Knops blood group on erythrocytes (York
and McCoy antigens), is also expressed by antigen-presenting cells. This regulates the
complement system by removing opsonized antigens, blocking the final steps of the
complement cascade. Membrane-bound CR1 also fosters antigen presentation to B
cells, whereas soluble CR1 has anti-inflammatory properties. CR1 gene polymorphisms
have been associated with susceptibility to complex diseases. In order to investigate
the association of CR1 polymorphisms with FS susceptibility, we developed a multiplex
sequence-specific assay to haplotype eleven polymorphisms in up to 367 FS patients
and 242 controls from an endemic area and 289 from a non-endemic area. We also
measured soluble CR1 (sCR1) in the serum of 53 FS patients and 27 controls and mRNA
levels in the peripheral bloodmononuclear cells of 63 genotyped controls. The haplotypes
CR1∗3B2B (with the York antigen–encoded by p.1408Met) and CR1∗3A2A (with
p.1208Arg) were associated with protection against FS (OR= 0.57, P= 0.027, andOR=
0.46, P= 0.014, respectively). In contrast, the CR1∗1 haplotype (with the McCoy antigen
– encoded by p.1590Glu) was associated with FS susceptibility (OR = 4.97, P < 0.001).
Heterozygote rs12034383∗A/G individuals presented higher mRNA expression than
homozygotes with the G allele (P = 0.04). The lowest sCR1 levels occurred in patients
with active disease before treatment (P= 0.036). Patients in remission had higher levels of
Oliveira et al. An Anti-inflammatory Role for CR1 in Fogo Selvagem
sCR1 than did healthy controls (P = 0.013). Among those under treatment, patients with
localized lesions also presented higher sCR1 levels than those with generalized lesions (P
= 0.0073). In conclusion, the Knops blood group seems to modulate susceptibility to the
disease. Furthermore, corticosteroid treatment might increase sCR1 serum levels, and
higher levels may play an anti-inflammatory role in patients with FS, limiting the distribution
of lesions. Based on these results, we suggest CR1 as a potential new therapeutic target
for the treatment of FS.
Keywords: pemphigus foliaceus, complement receptor 1, CR1, CD35, polymorphism, York blood antigen, McCoy
blood antigen, fogo selvagem
INTRODUCTION
Pemphigus foliaceus (PF) is an autoimmune blistering skin
disease presenting with erosions and crusts that may be
widespread and painful (1). Around the world, PF occurs
sporadically, with an incidence of 0.75–5 cases/million per
year (2, 3). In Brazil, it reaches up to 3% prevalence and
is also known as fogo selvagem (FS, meaning “wild fire”
in Portuguese) (2–6). While major immunopathological and
histological characteristics are similar in both endemic and
sporadic forms, the clinical presentation may differ (3, 7).
The etiology of FS is little understood, but environmental
factors are being considered. The bites of black mosquitoes
(Simuliidae) and sand flies (Phlebotominae) are associated with
an almost five times increased susceptibility to FS. Elements
delivered in the saliva of these hematophagous insects are
thought to trigger a cross-reaction against keratinocyte surface
epitopes in genetically susceptible individuals living in endemic
regions (8–10).
The intraepidermal blisters of PF are due to keratinocyte
detachment, a process known as acantholysis (11). FS patients
generate pathogenic IgG4 autoantibodies against desmoglein
1 (Dsg1) and occasionally and to a much lesser extent,
against Dsg3, which are important structural components of
desmosomes (1, 12). Altered cell-associated molecular patterns
activate the complement system, and this is responsible for
the recurrent observation of C3 component deposits along
the basement membrane zone and in intercellular spaces of
the perilesional and lesional epidermis of FS patients (13–
16). Deposits of complement membrane attack complexes, in
contrast, were only found in injured skin, whereas pathogenic
IgG4 anti-desmoglein 1 autoantibodies—which cannot activate
complement—were also abundant in apparently healthy tissue in
FS patients (14, 17).
Although not required to initiate blister formation (18, 19),
complement activation enhances acantholysis in cell culture
(20, 21). Furthermore, FS patients with active disease present
enhanced expression of the C1QA gene (an initiator molecule
of the classical pathway) and increased serum levels of C3 and
C-reactive protein (opsonins), of the cleaved factors resulting
from the activation of the alternative pathway (Ba factor), or of
the classical/lectin complement pathways (C4d factor), as well
as a trend to decreased mannose-binding lectin serine protease
2 levels, reflecting activation of the lectin pathway (14, 22–24).
Complement receptor 1 (CR1, CD35) is a glycoprotein with
∼200 kDa encoded by the CR1 gene (on chromosome region
1q32). The extracellular domain of the most common form
of CR1 is composed of a series of 30 repeating units named
short consensus repeats (SCRs). The SCRs are distributed in
four long homologous repeats (LHRs A, B, C, and D), arising
from duplication of a seven-SCR unit (Figure 1) (26–28). CR1
is primarily expressed in erythrocytes, B and T cells, neutrophils,
monocytes, and dendritic cells, as well as in neurons, microglia,
and the choroid plexus of the brain, in the membrane or in
soluble form (29). The soluble CR1 (sCR1) form results from
proteolytic cleavage in terminal secretory vesicles or in the cell
membrane (30, 31). Both CR1 forms act to regulate complement
activity by binding cleaved C3b and C4b components as well
as the complement cascade initiation molecules mannose-
binding lectin (MBL-2), ficolins (FCN1, FCN2, and FCN3), and
C1q deposited in altered cell components or pathogens. CR1
competes with serine proteases (MASPs) for the same binding
sites on the collagenous tails of MBL and FCNs, inhibiting
the initiation of the lectin pathway of complement (32). Upon
binding, the membrane-bound form of CR1 internalizes the
opsonized elements or presents them to other immune cells,
preventing the formation of the C5 convertase. This blocks the
formation of the membrane attack complex (MAC). CR1 might
also prevent excessive complement activation, acting as a cofactor
for the Factor I-mediated cleavage of soluble/bound C3b and
C4b (33). On the other hand, binding of opsonized elements
fosters antigen presentation to lymphocytes, increasing antibody
production, and the humoral response (29, 34). In the presence of
excess interleukin 2, CR1 expressed on activated T lymphocytes
generates regulatory T cells in secondary lymphoid organs, where
they may interact with B cells (35). In fact, CR1 ligation inhibits
B cell receptor-mediated activation and differentiation to plasma
cells (36).
In a recent study by our group that encompassed
polymorphisms of all genes encoding complement components,
we found evidence for an association with gene variants of almost
all complement elements previously detected in the epidermis or
with altered serum levels in FS patients. In addition, we identified
the association of four opsonin-binding complement receptors
(CR1-4, encoded by CR1, CR2, ITGAM, and ITGAX) (37).
Among them, we found that a CR1 haplotype with the major
rs6656401∗G allele was associated with increased susceptibility
to FS (37). This prompted us to thoroughly investigate the CR1
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FIGURE 1 | CR1 gene and protein structure and localization of the investigated SNPs. Each circular block represents a SCR (short consensus repeat, numbered
1–30), encoded by the exons 2–35, listed immediately above. There are three C4b binding sites (SCR 1-3, 8-10, and 15-17, in green and orange) and two C3b
binding sites (SCR 8-10 and 15-17, both in orange). SCRs 22-28 bind C1q, MBL, and ficolins, and SCRs 22, 24, and 25 (red dashed blocks) carry Knops blood
group antigens. The SNPs analyzed in this study are indicated in the gene, and the amino acid substitutions resulting from polymorphisms located in exons are
indicated on the protein. The dashed lines indicate coding exons of the main parts: the aminoterminal region (NH2, exon 1), transmembrane domain (TM, exons
36-37), the intracytoplasmic carboxi-terminal domain (IC COOH, exons 38-39), and the four long homologous repeats (LHR), responsible for complement
decay-accelerating, and cofactor activities (exons 1-7, 8-14, 15-21, 22-28). The functional sites in 8-10 and 15-17 are nearly identical. Repeats in green are required
for C4b binding and decay-accelerating activity, while those in orange are required for C3b and C4b binding and cofactor activity [adapted of (25)].
gene for other polymorphisms, including those encoding blood
group antigens that may affect the binding of C1q, MBL, and
FCNs, as well as to measure the expression of this gene at the
mRNA and soluble protein levels.
MATERIALS AND METHODS
Ethics Statement
This transversal case-control study was approved by the
National Committee for Ethics in Research (CONEP
02727412.4.0000.0096, protocol 505.988). All study participants
were informed about the research and signed a term of
informed consent.
Research Participants
For the association study, a total of 367 FS patients and
242 controls from an endemic area and 289 individuals from
a non-endemic area (among accompanying persons, health
workers, and other volunteers) were analyzed. The participants
were recruited from four centers: Hospital Adventista do
Pênfigo (Campo Grande-MS, Central Western Brazil), Lar da
Caridade (Uberaba-MG, Southwestern Brazil), Hospital das
Clínicas da Faculdade de Medicina de Ribeirão Preto (Ribeirão
Preto-SP, Southwestern Brazil), and Hospital das Clínicas da
Universidade Federal do Paraná (UFPR) (Curitiba-PR, South
Brazil). Data for both patients and controls were collected
through interviews and medical records. Inclusion criteria were:
written informed consent, being a resident in the endemic
region, and for the patients, FS diagnosis based on clinical
evidence and positive anti-Dsg1 serology. Exclusion criteria
were: consanguinity with a control or a patient and a familial
history of autoimmune diseases. All subjects were classified
according to ancestral origin, based on physical characteristics
and self-reported ancestry, as previously described (38, 39). The
demographic characteristics of the participants in this study are
listed in Table 1.
For the analysis of sCR1 levels in serum, we selected 53
FS patients and 27 healthy controls, matched for sex, age,
and previously genotyped for CR1 polymorphisms. Eighteen of
the patients were in complete remission, nine were without
treatment and nine were under immunosuppressive treatment;
35 patients presented with active fogo selvagem, six of whom
were still untreated and 29 of whom were already being treated.
Among all treated patients with known information regarding
the distribution of lesions, five had localized lesions, and 21 had
generalized lesions.
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In order to evaluate a possible correlation between CR1
polymorphisms and mRNA levels from peripheral blood
mononuclear cells (PBMC), we also genotyped 158 healthy
unrelated Euro-Brazilian volunteers, resident in Curitiba, Brazil,
and surrounding areas. We selected 63 individuals from this
TABLE 1 | Demographic data on endemic pemphigus foliaceus patients
and controls.
Controls FS patients
Endemic
n = 204
Non-
endemic
n = 256
Patients
n = 265
Localized
lesions
n = 44
Generalized
lesions
n = 80
Epidemiologic
data
Male (%) 99 (48.5) 106 (41.4) 121 (45.7) 18 (40.9) 32 (40.0)
Average age
(min-max)
44.75
(13–86)
33.64
(17–66)
37.42
(12–88)
28.5
(16–73)
38.55
(14–85)
Demographic
data
Central-
Western
(%)
177 (86.8) 0 206 (77.7) 31 (70.5) 57 (71.3)
Southwestern
(%)
5 (2.5) 0 56 (21.1) 12 (27.3) 21 (26.3)
South (%) 22 (10.8) 256 (100) 3 (1.1) 1 (2.3) 2 (2.5)
N, number of individuals; Central-Western, Campo Grande-MS; Southwestern, Ribeirão
Preto-SP. South, Curitiba-PR.
The total number of patients with localized or generalized lesions did not sum 265 due to
lack of proper diagnostic classification of some individuals.
group with the following inclusion criteria: no previous history of
an autoimmune disease, an obvious skin disease, and presenting
CR1 alleles and haplotypes associated with the disease (to
quantify mRNA levels).
CR1 Genotyping
Blood was collected with anticoagulant EDTA, and DNA was
extracted from PBMC as previously described, using phenol-
chloroform-isoamyl alcohol (40).
We selected 11 single nucleotide polymorphisms (SNPs) based
on [1] being previously associated with a disease, [2] being a
tag SNP with r² ≥ 0.8 in the European (Utah—USA), Mexican,
Colombian, or Yoruba populations of the 1000 Genomes Project
(41); and/or [3] by presenting a minor allele frequency higher
than 0.05. The CR1 SNPs evaluated were: rs6656401∗a>G
(intron 4); rs3849266∗c>T (intron 21); rs2274567∗a>G (exon
22, p.His1208Arg); rs12034598∗a>G (intron 24), rs1746659∗t>A
(intron 24), rs3737002∗c>T (exon 26, p.Thr1408Met, responsible
for the York blood group antigen); rs11118131∗c>T (intron
26); rs11118167∗t>C (intron 28); rs17047660∗a>G (exon 29,
p.Lys1590Glu, responsible for the McCoy blood group antigen);
rs4844610∗a>C (intron 37); rs12034383∗g>A (intron 37).
We developed two multiplex Polymerase Chain Reaction-
Sequence Specific Primer (PCR-SSP) reactions for simultaneous
identification of four SNPs and two simple PCR-SSPs for one SNP
each. All PCRs co-amplified a Human Growth Hormone (HGH)
or Human Leukocyte E antigen (HLA-E) fragment as internal
control. The sequences of specific and control primers are shown
inTable 2. All reactions were carried out in a final volume of 8µl,
containing 20 ng of genomic DNA, 0.2mM each of dNTP and
1x Coral Buffer (Invitrogen Life Technologies, Carlsbad, USA)
TABLE 2 | Primers for CR1 sequence-specific amplification.
Forward Primers Reverse primers
SNP Localization 5′→3′ Sequence SNP Localization 5′→3′ Sequence Fragment
Simple PCR 1 rs6656401 Intron 4 CTCTGTCTCCATCTTCTCA Generic Primer Intron 4 CATAGTTGTAGTTGGGGATTG 257 bp
CTCTGTCTCCATCTTCTCG
Multi 1 rs3849266 Intron 21 CTGATGGCTTGGGGTAT rs2274567 Exon 22 CTCAATCTGCATTGATCCAC 667 bp
CTGATGGCTTGGGGTAC CTCAATCTGCATTGATCCAT
Simple PCR 1 rs12034598 Intron 24 GCCTGGCATCATCAAGAAAA rs1746659 Intron 24 GGTTAGTGTTCAGAGGCAGA 1068 bp
GCCTGGCATCATCAAGAAAG GGTTAGTGTTCAGAGGCAGT
Multi 2 rs3737002 Exon 26 CCATTTGCCAGTCCTAC rs11118131 Intron 26 CAAGAAGAAGGGGTGATG 457 bp
CCATTTGCCAGTCCTAT CAAGAAGAAGGGGTGATA
Multi 2 rs11118167 Intron 28 GCCAATATGTGAATATTATTATCTTAT rs17047660 Exon 29 TTCTGGAGCTGTGCATTT 746 bp
GCCAATATGTGAATATTATTATCTTAC TTCTGGAGCTGTGCATTC
Multi 1 rs4844610 Intron 37 CTACACAAAACAGCCTTGTA rs12034383 Intron 37 AGATGTCCATGCCTTAAC 1080 bp
CTACACAAAACAGCCTTGTC AGATGTCCATGCCTTAAT
Control primers
Simple PCR 1, 2 and muli 1 HGHf TGCCTTCCCAACCATTCCCTTA HGHr CCACTCACGGATTTCTGTTGTGTTTC 431 bp
Multi 2 HLA-Ef CGGGACTGACTAAGGGGCGG HLA-Er GTAGCCCTGTGGACCCTCTTAC 324 bp
In bold: variant nucleotide. SNP, single nucleotide polymorphism; bp, base pairs; HGH, human growth hormone; HLA-E, Human leukocyte E antigen; f, forward; r, reverse; Multi,
multiplex PCR-SSP.
Frontiers in Immunology | www.frontiersin.org 4 November 2019 | Volume 10 | Article 2585
Oliveira et al. An Anti-inflammatory Role for CR1 in Fogo Selvagem
TABLE 3 | Primers for the CR1 Sequenom massARRAY iPLEX Platform.
SNP Localization 5′→3′ Forward Primer Sequence 5′→3′ Reverse Primer Sequence 5′→3′ Extended Primer Sequence
rs6656401 Intron 4 ACGTTGGATGGCATCATTTCCTTCTCTGTC ACGTTGGATGGACAGAAGAGCAAAGGACAC GTTTTTTCTCTGTCTCCATCTTCTC
rs3849266 Intron 21 ACGTTGGATGATAACTCGCCCCTCAATCTG ACGTTGGATGGCAGGCAACTGTGTTTATAC ACCTCAATCTGCATTGATCCA
rs3737002 Exon 26 ACGTTGGATGTCCAGGTCACTGTAAAACCC ACGTTGGATGAAGATGTCCCGACTGGAAAC CTATCAGTTTCCATTTGCCAGTCCTA
rs11118131 Intron 26 ACGTTGGATGGATGTCTATATTTGCCCAAG ACGTTGGATGGCATCTAGTCAAGGTTCAGG GGTATAAAGGAAAGGATGGTCTTGTA
rs11118167 Intron 28 ACGTTGGATGATGTGTGTAGTCACTTAGCC ACGTTGGATGATAATGGCAGATTTAAGGGC GCCAATATGTGAATATTATTATCTTA
rs17047660 Exon 29 ACGTTGGATGCAAGTTGGTGTTTGGAGCAG ACGTTGGATGGCATTTTCAACTTCTGGAGC TCACCTTCTGGAGCTGTGCATT
SNP, single nucleotide polymorphism.
(Supplementary Table 1). Thermal cycling began with 95◦C for
5min, followed by 33 (PCR-SSP-1) or 30 (PCR-SSP-2, 3 and 4)
cycles, for which each cycle began with 94◦C for 20 s and ended
with 72◦C (extension step) for 40 s (Supplementary Table 1).
We submitted the amplified fragments to an electrophoretic
run on 1% agarose gel, stained with Sybersafe (Invitrogen Life
Technologies, Carlsbad, USA).
Genotyping of the rs6656401, rs3849266, rs3737002,
rs11118131, rs11118167, rs17047660, and rs12034383
polymorphisms was performed with the iPLEX platform of
the MassARRAY system (Agena Bioscience, San Diego, USA) at
the Insitut für Klinische Molekularbiologie (IKMB), Christian-
Albrechts-Universität, Kiel, Germany (42), in order to technically
validate the results obtained by PCR-SSP. Genotypes were called
using the software MassARRAY Typer (v4.0) (Agena Bioscience,
San Diego, USA) with standard settings. The sequences of
specific and control primers are shown in Table 3.
sCR1 Quantification
We measured sCR1 levels in the serum (collected without
anticoagulant) by using a SEB123Hu ELISA kit (USCN Life
Science Inc., Wuhan, China) according to the manufacturer’s
instructions. Anti-Dsg1 and anti-Dsg3 levels were previously
measured using commercial ELISA kits (RG-M7593-D and RG-
7680-EC-D, respectively) (MBL, Woburn, USA) (43).
mRNA Quantification
Total RNA was isolated from PBMC lysed in TRIzol (Ambion,
Austin, USA) and reverse-transcribed with a High Capacity
cDNA Reverse Transcription Kit (Applied Biosystems,
Foster City, USA). Gene expression levels were quantified
by qPCR using TaqMan (Applied Biosystems, Foster City, USA)
chemistry for the CR1 (Hs00559348_m1, the most common CR1
transcript) and the housekeeping Glucuronidase Beta (GUSB)
gene (4333767F). All assays were performed in triplicate, and the
relative mRNA levels were normalized for mRNA expression of
the GUSB gene. Cq values (threshold cycle) were calculated using
the Viia 7 Software v1.2 Kit (Applied Biosystems, Foster City,
USA), and gene expression was calculated via the comparative
Cq method 2-11Cq (44).
Statistical and Bioinformatics Analysis
We obtained allele, genotype and two-SNP haplotype frequencies
by direct counting, and the hypothesis of Hardy-Weinberg
equilibrium was calculated with the exact test of Guo &
Thompson. We also compared haplotype distribution between
the investigated groups, using the exact test of population
differentiation of Raymond and Rousset. All tests were
performed in Arlequin v.5.1, a population genetics software
package (45).
We reconstructed extended haplotypes based on linkage
disequilibrium (LD) and phase information about the two-
SNP haplotypes obtained by PCR-SSP amplification, compared
the results with the haplotypes estimated using the EM
algorithm (Expectation-Maximization) implemented in PLINK
software (46), and found 2.9% of haplotypes with discrepant
results in accordance with the literature (47). We also
used PLINK for analysis of possible SNP interactions and
evaluated LD with Haploview 4.2 (48). We used Mega Software
v.6 to name the haplotypes according to the phylogenetic
nomenclature suggested by the literature (49) and adapted
them for recombinant haplotypes (Figure 2). We further
compared the distribution of polymorphisms and haplotypes in
patients and controls adjusted for the proportion of ancestry
groups using the Fisher exact test in the online software
VassarStats (VassarStats: Website for Statistical Computation;
available at: http://vassarstats.net). We adjusted all associations
for the possible effects of confounding factors (age, sex,
ancestry group) by logistic regression in total patient and
control groups using the software STATA v.9.2 (Statacorps,
Lakeway Drive, USA). To check for false discovery rate,
we used the correction of Benjamini and Hochberg (50)
on all significant results (“q” values lower than 0.05 were
considered significant).
Normality tests (D’Agostino & Pearson and Shapiro-
Wilk), correlation tests (Spearman), and non-parametric
comparisons of CR1 mRNA and sCR1 levels (Mann-
Whitney and Kruskal-Wallis tests) were carried out
using GraphPad Prism v.5.01 (GraphPad Software).
The use of different dosages of corticosteroids was
evaluated in the group of patients undergoing treatment
in order to verify whether there were differences
between them.
To predict the functional effects of associated SNPs, we
explored data from the ENCODE project contained in the
Regulome-DB (51) and Haploreg (52) databases. To evaluate the
effect of non-synonymous SNPs, we used Polyphen-2 (53) and
SNiPA (54).
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FIGURE 2 | Maximum parsimony tree of CR1 haplotypes with nucleotide changes and phylogenetic nomenclature. Underlined: amino acid substitutions.
RESULTS
CR1 Polymorphisms and Susceptibility to
Fogo Selvagem
None of the groups had genotype distributions that deviated
from those predicted under Hardy-Weinberg equilibrium. The
allele frequencies for each SNP did not differ between controls
and the Iberian population from the 1,000 Genomes Project.
In contrast, CR1 haplotype distributions differed between the
endemic and non-endemic controls, even within each ancestry
group (P< 0.0001). This led us to compare the patient groupwith
endemic and non-endemic control groups separately. We found
differences between the allelic distributions of isolated SNPs of
non-endemic controls and patients.
Comparing these two groups (Table 4,
Supplementary Table 2), we found evidence for a disease
association with the minor allele of rs17047660∗G in exon
29. This variant encodes p.1590Glu, which is responsible for
positive McCoy blood group antigen. Its allelic frequency was
higher among FS patients [OR = 3.77 (95%CI = 1.52–9.35), q
= 0.005]. rs17047660∗A/G heterozygote individuals were more
frequent among those with generalized lesions [OR = 3.06
(95%CI = 1.09–8.56), q = 0.025]. The rs3849266 within intron
21 occurs in a region with enhancer histone H3K4me1 marks,
binding at least 23 different regulatory proteins, according to the
ENCODE Database. rs3849266∗C/T presented an association
with increased susceptibility to the disease [OR = 1.54 (95%CI
= 1.03–2.31), q = 0.030]. We also found an additive effect of
carrying the “wild type” haplotype with rs3737002∗C in exon 26
(p.1408Thr, York negative) and rs11118131∗C in intron 26 [OR
= 1.5 (95%CI = 1.00–2.26), q = 0.049] with susceptibility to
severe FS. The minor allele rs2274567∗G, encoding p.1208Arg,
occurred more frequently among non-endemic controls than
among patients [OR= 0.58 (95%CI= 0.38–0.87), q= 0.035].
There was strong pairwise LD between the SNPs in intron
21 (rs3849266), exon 22 (rs2274567), exon 26 (rs3737002), and
intron 37 (rs12034383) (Supplementary Figure 1). Based on LD
and phase information, we haplotyped all SNPs in a subset of 146
FS patients and 126 controls from an endemic area and 156 from
a non-endemic area and identified 21 haplotypes (Figure 2). In
fact, we obtained the most conspicuous association results with
CR1 haplotypes (Table 5), revealing synergistic, additive/epistatic
effects between variants located on the same DNA string. The
carrier status of the ∗3B2B haplotype (GTHMCTKCA), the most
common haplotype encoding the York blood group antigen
(rs3737002, p.1408Met), protects against FS [OR = 0.57 (95%CI
= 0.35–0.93), q = 0.042] as well as against the localized form
of the disease [OR = 0.25 (95%CI = 0.089–0.72), q = 0.01].
In contrast with all other results, this association agreed for
comparisons with both endemic and non-endemic controls.
A similar protective effect was observed from carrying the
∗3A2A (GCRTTTKCG) haplotype, presenting p.1208Arg and
p.1408Thr [OR = 0.46 (95%CI = 0.25–0.85), q = 0.033]. This
protective effect agreed with the aforementioned association
results of rs2274567 (p.His1208Arg). In contrast, the frequency
of the ∗1 haplotype (GCHTCTKCG) was higher among FS
patients with both localized and generalized distributions of
cutaneous lesions than in controls (OR = 5.50 [95%CI = 1.84–
16.45], q = 0.016 and OR = 4.33 [95%CI = 1.74–10.77], q =
0.002, respectively).
Frontiers in Immunology | www.frontiersin.org 6 November 2019 | Volume 10 | Article 2585
Oliveira et al. An Anti-inflammatory Role for CR1 in Fogo Selvagem
TABLE 4 | Association of CR1 variants with endemic pemphigus foliaceus.
Controls FS patients
CR1 genetic
variants
Iberian n = 214
(%)
Endemic
control n (%)
Non-endemic
control n (%)
Patient n (%) Localized
lesion n (%)
Generalized
lesion n (%)
Patient vs. Non-endemic control
rs6656401 A>G n = 203 n = 234 n = 265 N = 44 N = 81 OR [95% CI] P (q) value
A 27 (12.60) 46 (11.33) 63 (13.46) 59 (11.13) 8 (9.09) 20 (12.35)
AA 2 (1.90) 2 (0.99) 1 (0.43) 2 (0.75) 1 (2.27) 0
AG 23 (21.50) 42 (20.69) 61 (26.07) 55 (20.75) 6 (13.64) 20 (24.69)
GG 82 (76.60) 159 (78.33) 172 (73.50) 208 (78.49) 37 (84.09) 61 (75.31)
A+ 44 (21.67) 62 (26.50) 57 (21.51) 7 (15.91) 20 (24.69)
rs3849266 C>T n = 182 n = 238 n = 233 n = 41 n = 76
T 68 (31.80) 103 (28.30) 122 (25.63) 125 (26.82) 19 (23.17) 38 (25.00)
CC 50 (46.70) 90 (49.45) 134 (56.30) 120 (51.50) 24 (58.54) 41 (53.95)
CT 46 (43.00) 81 (44.51) 86 (36.13) 101 (43.35) 15 (36.59) 32 (42.11) 1.54 [1.03–2.31] 0.036 (0.030)
TT 11 (10.30) 11 (6.04) 18 (7.56) 12 (5.15) 2 (4.88) 3 (3.95)
T+ 92 (50.55) 104 (43.70) 113 (48.50) 17 (41.46) 35 (46.05)
rs2274567 A>G
(p.His1208Arg)
n = 148 n = 232 n = 158 n = 28 n = 54
G 36 (16.80) 65 (21.96) 138 (29.74) 73 (23.10) 15 (26.79) 22 (20.37) 0.70 [0.51–0.98] 0.048 (0.035)
AA 73 (68.20) 94 (63.51) 110 (47.41) 93 (58.86) 14 (50.00) 32 (59.26)
AG 32 (29.90) 43 (29.05) 106 (45.69) 57 (36.08) 13 (46.43) 22 (40.74)
GG 2 (1.90) 11 (7.43) 16 (6.90) 8 (5.06) 1 (3.57) 0
G+ 54 (36.49) 122 (52.59) 65 (41.14) 14 (50.00) 22 (40.74)
rs3737002 C>T
(p.Thr1408Met)
n= 192 n= 246 n= 253 n= 43 n= 79
T 68 (31.80) 109 (28.39) 134 (27.24) 127 (25.10) 18 (20.93) 36 (22.78)
CC 50 (46.70) 103 (53.65) 133 (54.07) 144 (56.92) 27 (62.79) 47 (59.49)
CT 46 (43.00) 69 (35.94) 92 (37.40) 91 (35.97) 14 (32.56) 28 (35.44)
TT 11 (10.30) 20 (10.42) 21 (8.54) 18 (7.11) 2 (4.65) 4 (5.06)
T+ 89 (46.35) 113 (45.93) 109 (43.08) 16 (37.21) 32 (40.51)
rs11118131 C>T n = 177 n = 208 n = 225 n = 49 n = 71
T 35 (16.40) 75 (21.19) 103 (24.76) 89 (19.78) 15 (19.23) 26 (18.31) 0.74 [0.54–1.03] 0.08
CC 74 (69.20) 114 (64.41) 120 (57.69) 147 (65.33) 25 (64.10) 45 (63.38)
CT 31 (29.00) 51 (28.81) 73 (35.10) 67 (29.78) 13 (33.33) 26 (36.62)
TT 2 (1.90) 12 (6.78) 15 (7.21) 11 (4.89) 1 (2.56) 0
T+ 63 (35.59) 88 (42.31) 78 (34.67) 14 (35.90) 26 (36.62)
rs11118167 T>C n = 179 n = 232 n = 234 n = 41 n = 77
C 35 (16.40) 65 (18.16) 91 (19.61) 82 (17.52) 18 (21.95) 28 (18.18)
CC 2 (1.90) 4 (2.23) 5 (2.16) 7 (2.99) 2 (4.88) 2 (2.60)
CT 31 (29.00) 57 (31.84) 81 (34.91) 68 (29.06) 14 (34.15) 24 (31.17)
TT 74 (69.20) 118 (65.92) 146 (62.93) 159 (67.95) 25 (60.98) 51 (66.23)
C+ 61 (34.08) 86 (37.07) 75 (32.05) 16 (39.02) 26 (33.77)
rs17047660 A>G
(p.Lys1590Glu)
n = 185 n = 235 n = 247 n = 42 n = 77
G 3 (1.40) 10 (2.70) 6 (1.28) 23 (4.66) 4 (4.76) 9 (5.84) 3.77 [1.52–9.35] 0.002 (0.005)
AA 104 (97.20) 175 (94.59) 229 (97.45) 224 (90.69) 38 (90.48) 68 (88.31)
AG 3 (2.80) 10 (5.41) 6 (2.55) 23 (9.31) 4 (9.52) 9 (11.69) 3.56 [1.37–9.27] 0.009 (0.015)
GG 0 0 0 0 0 0 2.38 [1.01–5.62] 0.048 (0.035)
G+ 10 (5.41) 6 (2.55) 23 (9.31) 4 (9.52) 9 (11.69) 2.93 [1.18–7.24] 0.020 (0.020)
(Continued)
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TABLE 4 | Continued
Controls FS patients
CR1 genetic
variants
Iberian n = 214
(%)
Endemic
control n (%)
Non-endemic
control n (%)
Patient n (%) Localized
lesion n (%)
Generalized
lesion n (%)
Patient vs. Non-endemic control
rs4844610 A>C n = 203 n = 234 n = 265 n = 44 n = 81
A 23 (10.70) 47 (11.58) 63 (13.46) 59 (11.13) 8 (9.09) 20 (12.35)
AA 1 (0.90) 2 (0.99) 1 (0.43) 2 (0.75) 1 (2.27) 0
AC 21 (19.60) 43 (21.18) 61 (26.07) 55 (20.75) 6 (13.64) 20 (24.69)
CC 85 (79.40) 158 (77.83) 172 (73.50) 208 (78.49) 37 (84.09) 61 (75.31)
A+ 45 (22.17) 62 (26.50) 57 (21.51) 7 (15.91) 20 (24.69)
rs12034383 G>A n = 191 n = 242 n = 252 n = 43 n = 78
G 71 (33.20) 188 (49.21) 231 (47.73) 249 (49.40) 46 (53.49) 82 (52.56) 3.95 [1.08–14.34] 0.029
AA 44 (41.10) 50 (26.18) 70 (28.93) 69 (27.38) 10 (23.26) 17 (21.79)
AG 55 (51.40) 94 (49.21) 113 (46.69) 117 (46.43) 20 (46.51) 40 (51.28)
GG 8 (7.50) 47 (24.61) 59 (24.38) 66 (26.19) 13 (30.23) 21 (26.92)
G+ 141 (73.82) 172 (71.07) 183 (72.62) 33 (76.74) 61 (78.21)
All genotype distributions were in Hardy–Weinberg equilibrium. Associations were corrected for age, sex, and, if independent, for ancestry group distribution. P values were checked for
false discovery rate using the correction of Benjamini and Hochberg (“q” statistical significance level remained 0.05). n, number of individuals; OR, odds ratio in binary logistic regression;
CI, confidence interval; q, Benjamini-Hochberg corrected p-value.
sCR1 Levels and Susceptibility to Fogo
Selvagem
sCR1 levels differed according to treatment and disease
manifestations but not according to the genotypes of the
investigated SNPs and haplotypes (Figure 3). Patients in
complete remission on treatment had higher sCR1 levels (median
1.82 ng/mL) than did controls and patients that had not yet
initiated therapy (medians 1.23 and 0.61 ng/mL, P = 0.013 and
0.036, respectively). On the other hand, there was no difference
between sCR1 levels in controls and patients with active fogo
selvagem on treatment (medians 1.2 ng/mL vs. 1.39 ng/mL,
respectively, P = 0.188). However, those with localized lesions
revealed higher sCR1 levels than did patients with generalized
lesions (medians 2.39 ng/mL vs. 1.24 ng/mL, respectively, P =
0.0073). The sCR1 levels of patients with localized lesions on
immunosuppressive treatment were also significantly higher than
in controls (P= 0.0112). Of note, no difference in sCR1 levels was
found between patients treated with low and high corticosteroid
doses (P = 0.1897, data not shown).
CR1 mRNA Expression Levels
One out of eleven CR1 SNPs analyzed (rs12034383) was
associated with differential mRNA expression levels. Controls
with the rs12034383∗A/G genotype had higher mRNA levels
than controls with the rs12034383∗G/G genotype (median fold
changes 0.96 vs. 0.62, respectively, P = 0.04) (Figure 4). Carriers
of the protective GTHMCTKCA haplotype, which includes the
rs12034383∗A allele, presented instead lower mRNA expression
(P = 0.03) (Figure 5).
DISCUSSION
CR1 plays a major role in inhibiting the complement system,
removing immune complexes, and activating B cells, important
events that are deregulated in autoimmune diseases (35,
55, 56). Polymorphisms that alter CR1 gene expression or
protein activity are also common worldwide (57–60) and have
been associated with different infectious, autoimmune, and
neurological/neurodegenerative diseases (61–67). Those in exon
29 encode antigens of the Knops blood group system, the
22nd system recognized by the International Society of Blood
Transfusion (68): e.g., rs3737002 (p.Thr1408Met) defines the
York blood antigen and rs17047660 (p.Lys1590Glu), the McCoy
blood antigen (69, 70). These polymorphisms may modulate
the success of Plasmodium falciparum and Leishmania major, as
well as mycobacteria that invade erythrocytes and macrophages,
respectively (71–75). Most of the time, however, disease
associations are related to complement subversion/deregulation
and consequent alterations in phagocytosis and cytokine
release, even in infectious diseases (29, 76–78). For example,
in HIV infection, CR1 molecules expressed on erythrocytes
bind C3b-opsonized HIV particles. They act as cofactors
for factor I conversion of C3b to inactivated iC3b. This
allows the virus to survive anti-retroviral therapy and spread
as iC3b-opsonized particles, captured by CR2 on B cells,
and presented to other lymphocytes (79). In systemic lupus
erythematosus, a low CR1 density on neutrophils and other
phagocytes causes excessive C3 activation, the release of
proinflammatory cytokines, and immune-complex overload
(80–82). The risk for Alzheimer’s disease increases with the
preferential, low expression of a long CR1 isoform, which is
ineffective in the removal of beta-amyloid plaques (83–86).
Furthermore, CR1 polymorphisms also modulate the response
to eculizumab therapy, which targets complement protein
C5 (87).
Here, the York blood group, encoded by the CR1∗3B2B
haplotype, was associated with higher protection against FS. The
p.1408Met amino acid substitution (rs3737002∗T) is responsible
for this antigen and is considered as “probably damaging”
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TABLE 5 | Association of CR1 haplotypes with endemic pemphigus foliaceus.
Phylogenetic
Haplotype
Nucleotide
sequence
Patient groups
n/n total (%)
Control groups
n/n total (%)
OR 95% CI P (q) Model
*3B2B GTHMCTKCA Patient
57/292 (19.5)
Endemic
66/252 (26.2)
0.57 0.35–0.93 0.027 (0.042) Dominant
Localized lesion
5/25 (20)
Endemic
66/252 (26.2)
0.25 0.089–0.72 0.010 (0.025) Dominant
Localized lesion
5/25 (20)
Endemic
66/252 (26.2)
0.26 0.093–0.72 0.010 (0.029) Additive
Localized lesion
5/25 (20)
Non-endemic
71/312 (22.8)
0.35 0.12–1.00 0.052 (0.050) Dominant
Localized lesion
5/25 (20)
Non-endemic
71/312 (22.8)
0.35 0.12–0.99 0.049 (0.045) Additive
*1 GCHTCTKCG Patient
36/292 (12.3)
Non-endemic
32/252 (12.7)
4.97 2.13–11.59 <103 (0.004) Dominant
Patient
36/292 (12.3)
Non-endemic
32/252 (12.7)
4.76 2.08–10.87 <103 (0.008) Additive
Generalized lesion
9/52 (17.3)
Non-endemic
32/252 (12.7)
4.33 1.74–10.77 0.002 (0.012) Dominant and
additive
Localized lesion
3/25 (12)
Non-endemic
32/252 (12.7)
5.50 1.84–16.45 0.002 (0.016) Dominant
Localized lesion
3/25 (12)
Non-endemic
32/252 (12.7)
5.32 1.85–15.24 0.002 (0.021) Additive
*3A2A GCRTTTKCG Patient 25/292 (8.6) Non-endemic 43/252
(12.8)
0.46 0.25–0.85 0.014 (0.033) Dominant
Patient 25/292 (8.6) Non-endemic 43/252
(12.8)
0.49 0.27–0.89 0.020 (0.037) Additive
Haplotypes represented nine investigated CR1 SNPs (rs6656401, rs3849266, rs2274567, rs3737002, rs11118131, rs11118167, rs17047660, rs4844610, and rs12034383). One-
letter, underlined amino acid symbols are given instead of nucleotide substitutions, where appropriate. n, number of chromosomes; OR, odds ratio, corrected for age, ancestry group,
and sex distribution; CI, confidence interval.
*Fisher’s exact test. Dominant model: individuals with the haplotype were more frequent in one of the groups, regardless of whether homozygous or heterozygous. Additive model:
homozygote individuals were overrepresented in one of the groups, followed by heterozygotes, meaning that the haplotype presents an additive effect for increasing resistance/protection
against the disease.
FIGURE 3 | sCR1 serum levels in endemic controls and FS patients. P-values were obtained with the Mann-Whitney test. Interquartile median and range are indicated.
We excluded two outliers with very high levels (one with 7.14 ng/mL in controls and another with 10.2 ng/mL in FS patients with active disease, but under treatment).
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FIGURE 4 | Association between the expression of CR1 mRNA and CR1
rs12034383 polymorphism. Fold-change values were calculated through the
2–11Ct method. The horizontal bars in the clusters indicate the median.
P-values indicate a statistical significance at the 0.05 level and were calculated
by Mann–Whitney’s test. Scatter plots were constructed from the raw
non-normalized, fold change data using GraphPad 6.0 software (La Jolla,
California, USA).
(a Polyphen-2 score of 0.9 or higher and a CADD score of
19.52). This substitution modifies the first SCR in the LHR-
D module (SCR 22), responsible for the recognition of the
initiation molecules of the classical (C1q) and lectin (MBL and
FCNs) pathways, and may reduce the recognition of IgG1-
bound C1q as well as of MBL/FCNs (32) bound to exposed
glycosilated/acetylated residues on desmosomes and epithelial
cells, decreasing internalization of neoantigens by antigen-
presenting cells (Figure 6).
As expected, the most ancestral ∗1 haplotype, encoding
p.1408Thr, seems to increase susceptibility to FS. Interestingly,
although this association was found by comparing patients with
non-endemic controls, a CR1 haplotype with p.1408Thr was
found to increase FS susceptibility 1.4x within the endemic
population in our previous study (37). Furthermore, the
same haplotype has recently been associated with increased
susceptibility to the more severe multibacillary clinical forms of
leprosy (25).
On the other hand, the p.1408Met amino acid substitution
was also recently associated with susceptibility to idiopathic
pulmonary fibrosis (88). Affected patients present an increase
of serum proteins of the complement cascade and higher
complement activation in the lung (89). The same allele
was also reported to increase the susceptibility to late-onset
Alzheimer’s disease in Han Chinese (90). Compared to the
York antigen, the opposite is expected to occur with the amino
acid substitution that creates the McCoy “b” antigen in SCR25,
namely p.Lys1590Glu (rs17047660∗G). This SNP is also deemed
to be damaging (although with a low Polyphen score: 0.597)
or deleterious, according to SIFT (score of 0.02). It increases
the amount of glutamic acid residues in a sequence of only 10
residues, strengthening the negative charge already provided by
FIGURE 5 | Association between the expression of CR1 mRNA and the
*1.3B2B– GCHMCTKCA haplotype. +GCHMCTKCA: homozygote or
heterozygote individuals. Fold-change values were calculated through the
2–11Ct method. The horizontal bars in the clusters indicate the median.
P-values indicate a statistical significance at the 0.05 level and were calculated
by Mann–Whitney’s test. Scatter plots were constructed from the raw
non-normalized, fold change data using GraphPad 6.0 software (La Jolla,
California, USA).
Glu at the 1595 and 1597 positions and thus most probably
increasing the affinity of this LHR-D domain for C1q/MBL/FCNs
(91). This could explain the association found with increased
susceptibility to FS, since it could potentially increase the capture
of complement-opsonized elements, their internalization, and
consequent B cell activation (Figure 6). The association found
with the McCoy antigen (p.1590Glu), however, did not resist
correction for demographic factors, which may stem from
its higher frequency in African-derived populations and the
small sample size of this study. Interestingly, homozygosity
for p.1590Glu was also associated with higher susceptibility to
repetitive malaria-associated seizures in patients with cerebral
malaria (66). The susceptibility associations found for the
intronic polymorphisms rs6656401∗G and rs3849266∗T are in
accordance with our previous results (37), but the latter may also
result from strong linkage disequilibrium with rs3737002.
Last, but not least, we found a protective association with
the ∗3A2A haplotype, containing the p.1208Arg (rs2274567∗G)
amino acid substitution. Among the investigated SNPs, this
allele was, as expected, also associated with FS resistance.
However, both associations only occurred when comparing
patients with non-endemic controls. Thus, we recommend
caution in interpreting these results until they are replicated in
an independent sample.
In accordance with the proposed anti-inflammatory role
of the York antigen in disease resistance, we found an
association of higher levels of sCR1, a molecule known for
its anti-inflammatory properties (92), with less severe clinical
presentation of FS, disease remission, and corticoid therapy.
This leads us to suggest that sCR1 plays a protective role
in the evolution of the disease. The soluble CR1 molecule
shares all LHR domains with exosomal-bound CR1 and cell
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FIGURE 6 | Proposed role of CR1 polymorphisms of the Knop blood group and soluble CR1 in susceptibility to endemic pemphigus foliaceus. (A) The p.1408Met
amino acid substitution (York antigen) in the SCR22 module of the protein is proposed to reduce the affinity of CR1 molecules for C1q/collectin/ficolin to IgG1-bound
C1q as well to exposed glycosilated/acetylated residues on desmosomes and epithelial cells, decreasing internalization of neoantigens by antigen-presenting cells.
(B) In contrast, CR1 molecules with p.1590Glu (McCoy antigen) are proposed to have enhanced affinity for C1q/collectin/ficolins due to a negative charge already
provided by Glu at the 1595 and 1597 positions, increasing the internalization of cell debris and other opsonized complexes, fostering the autoimmune reaction by
renewing the presentation of self-peptides, and consequent B and T cell activation. (C) The soluble CR1 molecule has anti-inflammatory properties. As cell
membrane-bound CR1, sCR1 acts as a cofactor for the Factor I-mediated cleavage of soluble/bound C3b and C4b, reducing opsonization and phagocytosis.
Furthermore, sCR1 and exosomal-bound CR1 are unable to mediate the LHR-D-mediated internalization of opsonized complexes by phagocytes, inhibiting both
complement activation, and complement-driven phagocytosis (by the author).
membrane-bound CR1, as well as all functions mediated by
LHRs A-C, including the ability to cleave C4b, accelerating
the decay of C3 and C5 convertases, and to cleave C3b,
reducing opsonization and phagocytosis (27, 93). Nevertheless,
sCR1 and exosomal-bound CR1 are unable to mediate the
LHR-D-mediated internalization of opsonized complexes by
phagocytes, thus acting as a “sink” for initiation molecules
of the complement cascade and inhibiting both complement
activation and complement-driven phagocytosis (92). Taking
into account that human sCR1 has been demonstrated to reduce
acute inflammation and autoimmunity, even preventing disease
progression in a rat arthritis model (94, 95), and as the potential
application of sCR1 in therapeutic settings has been shown
(96), its role in susceptibility to pemphigus and its clinical
evolution might be highly relevant. A longitudinal follow-up
study would be necessary to find out whether patients with
localized lesions that have progressed to the generalized form
also present a decline in sCR1 concentration. In the present
study, CR1 genotypes were not correlated with sCR1 serum
levels, which might rely on the fact that the sCR1 form does not
result from alternative splicing of the gene but from proteolytic
cleavage (31).
CR1 gene expression was higher in healthy individuals with
the genotype A/G (rs12034383) than in G/G homozygotes. This
latter genotype is also associated with impaired removal of
amyloid Aß in the cerebrospinal fluid of Alzheimer patients
compared with A/A homozygotes (83). Interestingly, the
recombinant ∗1.3B2B (GCHMCTKCA) haplotype, containing the
proposed protective York antigen (p.1408Met), was associated
with lower gene expression, lending support to the hypothesis
that low CR1 levels would protect against the production of
autoantibodies, as previously discussed.
In conclusion, our data lead us to suggest that CR1
polymorphisms of the Knops blood group modulate
susceptibility to FS. Furthermore, higher sCR1 levels may
limit FS lesions and promote/accelerate disease remission.
CR1 may thus be regarded as a candidate for new therapeutic
interventions in the disease.
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Supplementary Figure 1 | Pairwise linkage disequilibrium plot based on
investigated CR1 SNPs. Colors are indicative of D’/logarithm of odds (LOD), and
values correspond to r2. Bright red represents LOD score for LD ≥ 2 and D = 1,
shades of pink/red represent LOD ≥ 2 and D < 1, blue represents D = 1 but LOD
< 2, and white squares represent LOD< 2 and D < 1. (A) Euro-Brazilian patients.
(B) Euro-Brazilian controls. (C) Afro-Brazilian patients. (D) Afro-Brazilian controls.
The SNPs rs12034598 and rs1746659 are not represented in the plot because
they were not genotyped for all individuals.
Supplementary Table 1 | PCR conditions. HGH was used as an internal
amplification control for simple PCR 1, 2 and multiplex 1; HLA-E was used as an
internal amplification control for multiplex PCR 2; Simple PCR 1: CR1 forward
primer-1 pair detects rs6656401 alleles; Simple PCR 2: CR1 forward primer-1 pair
detects rs12034598 alleles and CR1 reverse primer-1 pair detects rs1746659
alleles; Multiplex PCR 1: CR1 forward primer-1 pair detects rs3849266 alleles and
CR1 reverse primer-1 pair detects rs2274567 alleles; and CR1 forward primer-2
pair detects rs4844610 alleles and CR1 reverse primer-2 pair detects rs12034383
alleles; Multiplex PCR 2: CR1 forward primer-1 pair detects rs3737002 alleles and
CR1 reverse primer-1 pair detects rs11118131 alleles; and CR1 forward primer-2
pair detects rs11118167 alleles and CR1 reverse primer-2 pair detects
rs17047660 alleles; C, Celsius; min: minute; sec: seconds.
Supplementary Table 2 | Allele and genotype distributions of CR1
polymorphisms investigated in this study.
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